Advertisement AltheaDx introduces New NGS oncology panel for drug development programs - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

AltheaDx introduces New NGS oncology panel for drug development programs

AltheaDx has launched its CLIA-validated, next-generation sequencing (NGS) assay, AltheaDx Oncology Panel (AOP 50), designed for multiple drug and companion diagnostic development programs.

Based on Thermo Fisher Scientific’s Oncomine Focus Assay, the AOP 50 Assay allows concurrent analysis of DNA and RNA from solid tumors, enabling sequencing of 35 hotspot genes and 23 fusion genes in a single workflow on the Ion PGM System.

With the increasing importance of genetic translocations in oncology, the AOP 50 Assay also enables gene fusion transcript detection and reduces the complexity of performing alternate fusion detection methods such as fluorescence in situ hybridization (FISH).

Leveraging the low-sample input requirement from formalin-fixed paraffin-embedded (FFPE) tissue (10 ng extracted nucleic acid for a total of 20 ng per sample) of the Ion AmpliSeq technology, AOP 50 enables accurate and reliable analysis of sequences from different tumor sample types, including small biopsies and fine needle aspirates.

The biomarkers included in the AOP 50 Assay are derived from Thermo Fisher’s Oncomine Focus Assay and have been selected using the Oncomine Knowledgebase, which is one the world’s largest collections of oncology data, long trusted by pharmaceutical companies.

AltheaDx president and COO Jorge Garces said: "We are excited to add AOP 50 to our growing portfolio of services. These tools will continue to enable clinical research efforts crucial to improving patient care and therapeutic decision-making for oncology professionals in the future."

"We are pleased that AltheaDx joins a growing list of companies that see real value in using Oncomine assay technology to expand their services," said Mike Nolan, Vice President and General Manager of Oncology for Thermo Fisher Scientific.

"Targeted NGS panels are playing a key role in the drug development process, which will prove to have a positive effect in the clinical cancer community."